within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BH06_Gemigliptin;

model Gemigliptin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.62,
    Cl = 4.722222222222222e-06,
    adminDuration = 600,
    adminMass = 50 / 1000000,
    adminCount = 1,
    Vd = 0.101,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.013833333333333333,
    Tlag = 15.0,
    Vdp = 0.177,
    k12 = 5.75e-06,
    k21 = 5.75e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Gemigliptin</td></tr><tr><td>ATC code:</td><td>A10BH06</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>50</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>101</td><td>L</td></tr>
    <tr><td>clearance:</td><td>17</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Gemigliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used to improve glycemic control in people with type 2 diabetes mellitus. It is an orally administered antidiabetic agent. It has been approved for clinical use in some countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers following single oral administration.</p><h4>References</h4><ol><li><p>Noh, YH, et al., &amp; Bae, KS (2012). Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers. <i>Clinical therapeutics</i> 34(5) 1182–1194. DOI:<a href=\"https://doi.org/10.1016/j.clinthera.2012.04.001\">10.1016/j.clinthera.2012.04.001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22534255/\">https://pubmed.ncbi.nlm.nih.gov/22534255</a></p></li><li><p>Choi, HY, et al., &amp; Bae, KS (2014). Evaluation of pharmacokinetic drug interactions between gemigliptin (dipeptidylpeptidase-4 inhibitor) and glimepiride (sulfonylurea) in healthy volunteers. <i>Drugs in R&amp;D</i> 14(3) 165–176. DOI:<a href=\"https://doi.org/10.1007/s40268-014-0054-8\">10.1007/s40268-014-0054-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24962635/\">https://pubmed.ncbi.nlm.nih.gov/24962635</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.A.A10BH06 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Gemigliptin;
